Clinical Trials Directory

Trials / Completed

CompletedNCT01621945

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)

Phase 3, Vaccinal Activity Assessment of MenBVac Against Neisseria Meningitidis B:14,P1.7,16 Strain in Child

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
4 Years – 8 Years
Healthy volunteers
Accepted

Summary

The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (\>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMenBvacBlood test

Timeline

Start date
2012-04-01
Primary completion
2013-04-01
Completion
2013-09-01
First posted
2012-06-18
Last updated
2014-09-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01621945. Inclusion in this directory is not an endorsement.

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vacc (NCT01621945) · Clinical Trials Directory